Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BLFS Stock Forecast 2025-2026
$25.46
Current Price
$1.23B
Market Cap
Buy 10
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to BLFS Price Targets
+33.5%
To High Target of $34.00
+25.7%
To Median Target of $32.00
+17.8%
To Low Target of $30.00
BLFS Price Momentum
-3.9%
1 Week Change
-5.8%
1 Month Change
-3.0%
1 Year Change
-1.9%
Year-to-Date Change
-14.0%
From 52W High of $29.62
+33.3%
From 52W Low of $19.10
📊 TOP ANALYST CALLS
Did BLFS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if BioLife Solutions is one of their latest high-conviction picks.
Latest BLFS Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, BLFS has a bullish consensus with a median price target of $32.00 (ranging from $30.00 to $34.00). The overall analyst rating is Strong Buy (9.8/10). Currently trading at $25.46, the median forecast implies a 25.7% upside. This outlook is supported by 10 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Yi Chen at HC Wainwright & Co., suggesting a 17.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BLFS Analyst Ratings
10
Buy
0
Hold
0
Sell
BLFS Price Target Range
Low
$30.00
Average
$32.00
High
$34.00
Current: $25.46
Latest BLFS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BLFS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 24, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $32.00 |
| Aug 8, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $32.00 |
| May 13, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $30.00 |
| Mar 6, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $30.00 |
| Jan 8, 2025 | Northland Capital Markets | Carl Byrnes | Outperform | Maintains | $31.00 |
| Dec 19, 2024 | Benchmark | Robert Wasserman | Buy | Reiterates | $30.00 |
| Dec 13, 2024 | Keybanc | Paul Knight | Overweight | Maintains | $33.00 |
| Nov 18, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $27.00 |
| Nov 13, 2024 | TD Cowen | Steven Mah | Buy | Maintains | $31.00 |
| Nov 13, 2024 | Craig-Hallum | Matt Hewitt | Buy | Maintains | $32.00 |
| Sep 30, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Initiates | $29.00 |
| Aug 12, 2024 | Craig-Hallum | Matt Hewitt | Buy | Maintains | $30.00 |
| Aug 9, 2024 | Northland Capital Markets | Carl Byrnes | Outperform | Maintains | $28.00 |
| Jul 17, 2024 | TD Cowen | Steven Mah | Buy | Maintains | $26.00 |
| May 13, 2024 | Benchmark | Robert Wasserman | Buy | Upgrade | $25.00 |
| Apr 4, 2024 | Jefferies | Matthew Stanton | Buy | Initiates | $22.00 |
| Aug 10, 2023 | Craig-Hallum | Matt Hewitt | Buy | Maintains | $23.00 |
| Aug 9, 2023 | TD Cowen | Max Masucci | Outperform | Maintains | $25.00 |
| Aug 9, 2023 | Lake Street | Thomas Flaten | Buy | Maintains | $25.00 |
| Jul 17, 2023 | Stephens & Co. | Overweight | Maintains | $N/A |
Biolife Solutions Inc. (BLFS) Competitors
The following stocks are similar to BioLife Solutions based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BLFS
BioLife Solutions
mkt cap
1.28B
Biolife Solutions Inc. (BLFS) Financial Data
Biolife Solutions Inc. has a market capitalization of $1.23B with a P/E ratio of -57.9x. The company generates $100.14M in trailing twelve-month revenue with a -3.2% profit margin.
Revenue growth is +31.2% quarter-over-quarter, while maintaining an operating margin of -0.3% and return on equity of -5.2%.
Valuation Metrics
Market Cap
$1.23B
Enterprise Value
$1.17B
P/E Ratio
-57.9x
PEG Ratio
0.5x
Price/Sales
12.2x
Growth & Margins
Revenue Growth (YoY)
+31.2%
Gross Margin
+63.9%
Operating Margin
-0.3%
Net Margin
-3.2%
EPS Growth
-8.2%
Financial Health
Cash/Price Ratio
+6.4%
Current Ratio
4.7x
Debt/Equity
5.8x
ROE
-5.2%
ROA
-0.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Biolife Solutions Inc. (BLFS) Business Model
About Biolife Solutions Inc.
What They Do
Provider of bioproduction tools for cell and gene therapy.
Business Model
The company generates revenue by offering a range of biopreservation media, automated thawing devices, and storage solutions that are essential for preserving and transporting biological materials. Their products cater to the needs of sectors like regenerative medicine, biobanking, and drug discovery, ensuring the safe handling and preservation of vital biological samples.
Additional Information
Headquartered in Bothell, Washington, Biolife Solutions is strategically positioned to meet the evolving demands of the global biopharmaceutical sector. Their innovations significantly contribute to advancing therapeutic research and the development of treatments, impacting the healthcare industry extensively.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
159
CEO
Mr. Roderick de Greef
Country
United States
IPO Year
1992
Website
www.biolifesolutions.comBiolife Solutions Inc. (BLFS) Latest News & Analysis
Latest News
Quick Summary
BioLife Solutions, Inc. (NASDAQ: BLFS) opened a new conference and laboratory facility in Bothell, WA, aimed at advancing biopreservation and cell processing innovation.
Why It Matters
The new facility enhances BioLife Solutions' capabilities, potentially driving growth in the cell and gene therapy market, which could lead to increased revenue and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
BioLife Solutions to Participate in Upcoming Investor Conferences in November and December 2025
19 days ago
Quick Summary
BioLife Solutions, Inc. (NASDAQ: BLFS) will participate in several investor conferences from November to December 2025, including events hosted by Raymond James and Jefferies.
Why It Matters
BioLife Solutions' participation in key investor conferences signals active engagement with the investment community, potentially boosting visibility and investor confidence in their CGT market position.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
The Zacks Medical products industry faces steady demand but is experiencing growth pressure due to macro headwinds in 2025. Key companies include BSX, PODD, BLFS, and ALUR.
Why It Matters
Steady demand in the medical products industry suggests resilience, but macroeconomic challenges may limit growth in 2025. Companies like BSX, PODD, BLFS, and ALUR indicate strong fundamentals amidst this environment.
Source: Zacks Investment Research
Market Sentiment:
Negative
New Strong Buy Stocks for November 10th
26 days ago
Quick Summary
Five stocks have been added to the Zacks Rank #1 (Strong Buy) List, indicating a strong buy recommendation for potential investors.
Why It Matters
Stocks on the Zacks Rank #1 list indicate strong potential for growth, signaling favorable market conditions and investment opportunities for high returns.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
BioLife Solutions, Inc. (BLFS) will hold its Q3 2025 earnings call on November 6, 2025, at 4:30 PM EST, featuring key executives and analysts from various investment firms.
Why It Matters
BioLife Solutions' Q3 earnings call signals upcoming insights into financial performance, growth potential, and strategic direction, impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Cell Processing revenue reached $25.4M, up 33% YoY, with a GAAP gross margin of 62%. 2025 revenue guidance raised to $93.0M-$94.0M. Conference call at 4:30 PM ET today.
Why It Matters
Strong revenue growth and improved margins indicate robust business performance. Raised guidance for 2025 suggests confidence in future earnings, making the company an attractive investment opportunity.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About BLFS Stock
What is Biolife Solutions Inc.'s (BLFS) stock forecast for 2026?
Based on our analysis of 15 Wall Street analysts, Biolife Solutions Inc. (BLFS) has a median price target of $32.00. The highest price target is $34.00 and the lowest is $30.00.
Is BLFS stock a good investment in 2026?
According to current analyst ratings, BLFS has 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $25.46. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BLFS stock?
Wall Street analysts predict BLFS stock could reach $32.00 in the next 12 months. This represents a 25.7% increase from the current price of $25.46. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Biolife Solutions Inc.'s business model?
The company generates revenue by offering a range of biopreservation media, automated thawing devices, and storage solutions that are essential for preserving and transporting biological materials. Their products cater to the needs of sectors like regenerative medicine, biobanking, and drug discovery, ensuring the safe handling and preservation of vital biological samples.
What is the highest forecasted price for BLFS Biolife Solutions Inc.?
The highest price target for BLFS is $34.00 from at , which represents a 33.5% increase from the current price of $25.46.
What is the lowest forecasted price for BLFS Biolife Solutions Inc.?
The lowest price target for BLFS is $30.00 from Yi Chen at HC Wainwright & Co., which represents a 17.8% increase from the current price of $25.46.
What is the overall BLFS consensus from analysts for Biolife Solutions Inc.?
The overall analyst consensus for BLFS is bullish. Out of 15 Wall Street analysts, 10 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $32.00.
How accurate are BLFS stock price projections?
Stock price projections, including those for Biolife Solutions Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 6, 2025 6:08 PM UTC